Fenfluramine (HCl)

Fenfluramine (HCl) is used in obesity and also has anorectic effects. Fenfluramine (HCl) is a racemic chemical, closely related to amphetamine. It was introduced as an anorexigenic drug more than a decade ago in Europe. Its d-isomer, d-fenfluramine is about twice as potent an anorexigenic drug as fenfluramine, suggesting that all of the fenfluramine activity reside in the d-form.

Fenfluramine (HCl) is primarily indicated in conditions like Obesity, and can also be given in adjunctive therapy as an alternative drug of choice in Hypertension, Maturity onset diabetes, Seizures.

Fenfluramine (HCl) is contraindicated in conditions like Depression, Mania, Cardiovascular disease,

The severe or irreversible adverse effects of Fenfluramine (HCl), which give rise to further complications include Tachycardia, Impotence, Anorexia, Coma, Depression, Dizziness, Respiratory depression, Abdominal cramps. Fenfluramine (HCl) produces potentially life-threatening effects which include Blood dyscrasias, Pulmonary hypertension, which are responsible for the discontinuation of Fenfluramine (HCl) therapy. The signs and symptoms that are produced after the acute over dosage of Fenfluramine (HCl) include Flushing, Tachycardia, Cardiac arrhythmias, Convulsions, Coma, Hyperthermia, Hallucinations, Sweating, Tachypnea, Hyperpyrexia, Tremor, Mydriasis, Nystagmus, Excitation, Increased tendon reflexes, Chest pain. The symptomatic adverse reactions produced by Fenfluramine (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Decreased appetite, Dizziness, Drowsiness, Irritability, Nausea, Vomiting, Diarrhea, Restlessness, Insomnia, Dry mouth, Rashes, Lethargy, Impotence, Loss of libido, Urinary frequency, Drooling, Pyrexia, Abnormal ECHO, Malaise, Asthenia.

Avoid Fenfluramine in patients with pulmonary hypertension, past or current history of cardiovascular or cerebrovascular disease, psychiatric disease, glaucoma, epilepsy, history of drug abuse. It should be used with extreme caution in elderly or during pregnancy or lactation. Avoid abrupt withdrawal. Patient should observe caution while driving or performing other task requiring alertness because it may produce dizziness, extreme fatigue and depression. It should be used with caution and monitor blood pressure (B.P) in patients with mild hypertension. Dose titration and dose discontinuance may be necessary in epileptic patients. Height and weight should be monitored as fenfluramine may cause growth retardation.

Drug should not be given to Pediatrics, Pregnant Mothers, Geriatrics, and Neonates. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

0.285 mg/kg (0.28 (0.285)) 12 hourly PO — Intially for 1 Week 0.57 to 1.142 mg/kg (0.86 (0.856)) 12 hourly PO — Maintenance, As Required

( ) — Not recommended in this age group

( ) — Not recommended in this age group

Fenfluramine (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAmitriptyline (HCl)HalothaneHuman InsulinInsulin GlulisineInsulin LisproIprindoleLikely interaction of FENFLURAMINE HYDROCHLORIDE reducing the ANTIDEPRESSANT effect of IPRINDOLE.MajorMay need to avoid combinationIsocarboxazidLofepramine (HCl)Likely interaction of FENFLURAMINE HYDROCHLORIDE reducing the ANTIDEPRESSANT effect of LOFEPRAMINE. MajorParoxetineQuinagolide (HCl)Rauwolfia ReserpineReserpineTranylcypromine (Sulphate) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Tab Store in a well closed container, at room temperature. Protect from Moisture.